A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of LY3839056 in Healthy Participants
A Phase 1, Randomized, Placebo-Controlled, Investigator- and Participant-Blinded, Single Ascending Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of LY3839056 in Healthy Participants
The main purpose of this study is to see if LY3839056 is safe and well tolerated when given as a single dose into a vein intravenous (IV) or under the skin subcutaneous (SC) in healthy participants. The study will also measure how much LY3839056 gets into the blood and how long it takes the body to remove it. The study will last up to 17 weeks and includes a stay of about 6 days at the clinical research unit.
Studieöversikt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Studietyp
Studietyp
Inskrivning (Beräknad)
Inskrivning
Fas
Fas
- Fas 1
Kontakter och platser
Studiekontakt
Studiekontakt
- Namn: 1-877-CTLILLY (1-877-285-4559) or
- Telefonnummer: 1-317-615-4559
- E-post: LillyTrials@lilly.com
Studieorter
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Kina, 200040
- Huashan Hospital, Fudan University (复旦大学附属华山医院) 12 Urumqi Middle Road
-
Kontakt:
- Xiaojie Wu, PhD
- Telefonnummer: 13524686330
-
-
Deltagandekriterier
Urvalskriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Key Inclusion Criteria:
- Are overtly healthy as determined by medical evaluation, including medical history, physical examination, laboratory tests, and Cardiac Monitoring.
- Have clinical laboratory test results within normal reference range for the population or the clinical research site, or results with acceptable deviations that are judged to be not clinically significant by the investigator.
- Have venous access sufficient to allow for IV drug delivery and blood sampling as per the protocol.
- Have a body mass index within the range of 18.0 to 32.0 kg/m².
- Participants assigned male or female at birth, including individuals of childbearing potential (IOCBP), may participate in this trial.
- Contraceptive use by participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
Key Exclusion Criteria:
- Are immunocompromised or have a history of a primary immunodeficiency, splenectomy, or any underlying condition that predisposes the participant to infection.
- Have a history or presence of cardiovascular, respiratory, hepatic, ophthalmological, renal, gastrointestinal, endocrine, hematological, neurological, or psychiatric disorders.
- Had any surgical procedure (except for minor surgery requiring local or no anesthesia and without any complications or sequelae) within 12 weeks prior to screening, or any planned surgical procedure scheduled to occur during the study.
- Have a clinically significant history of multiple or severe allergies or an anaphylactic reaction to prescription or nonprescription drugs or food.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Grundläggande vetenskap
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Dubbel
Antal vapen
Vapen och interventioner
Deltagargrupp / ArmDeltagargrupp / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Experimentell: Cohort 1 IV
Participants will receive LY3839056 Intravenously |
LY3839056 Administered Intravenously
Andra namn:
|
|
Experimentell: Cohort 2 IV
Participants will receive LY3839056 Intravenously |
LY3839056 Administered Intravenously
Andra namn:
|
|
Experimentell: Cohort 3 IV
Participants will receive LY3839056 Intravenously |
LY3839056 Administered Intravenously
Andra namn:
|
|
Experimentell: Cohort 4a IV
Participants will receive LY3839056 Intravenously |
LY3839056 Administered Intravenously
Andra namn:
|
|
Experimentell: Cohort 4b SC
Participants will receive LY3839056 Subcutaneously |
LY3839056 Administered Subcutaneously
Andra namn:
|
|
Experimentell: Cohort 5 IV
Participants will receive LY3839056 Intravenously |
LY3839056 Administered Intravenously
Andra namn:
|
|
Experimentell: Cohort 6a IV
Participants will receive LY3839056 Intravenously |
LY3839056 Administered Intravenously
Andra namn:
|
|
Experimentell: Cohort 6b SC
Participants will receive LY3839056 Subcutaneously |
LY3839056 Administered Subcutaneously
Andra namn:
|
|
Placebo-jämförare: Placebo IV
Participants will receive Placebo Intravenously |
Placebo Administered Intravenously
Andra namn:
|
|
Placebo-jämförare: Placebo SC
Participants will receive Placebo Subcutaneously |
Placebo Administered Subcutaneously
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
To evaluate the safety and tolerability of LY3839056 following single-dose administration (IV or SC) in healthy participants.
Tidsram: Baseline through Day 85
|
Frequency of AEs, TEAEs, SAEs, and Discontinuation due to TEAEs. |
Baseline through Day 85
|
Sekundära resultatmått
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
PK: Cmax
Tidsram: Predose on Day 1 up to Day 85
|
Maximum Observed Concentration (Cmax) of LY3839056 following single SC or IV dose |
Predose on Day 1 up to Day 85
|
|
PK: AUC
Tidsram: Predose on Day 1 up to Day 85
|
Area Under the Concentration Versus Time Curve (AUC) of LY3839056 following single SC or IV dose |
Predose on Day 1 up to Day 85
|
|
PK: t1/2
Tidsram: Predose on Day 1 up to Day 85
|
Half Life (t1/2) of LY3839056 following single SC or IV dose |
Predose on Day 1 up to Day 85
|
|
PK: F%
Tidsram: Predose on Day 1 up to Day 85
|
Bioavailability (F%) of LY3839056 following single SC dose |
Predose on Day 1 up to Day 85
|
Samarbetspartners och utredare
Sponsor
Sponsor
Utredare
Utredare
- Studierektor: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Studiestart
Primärt slutförande (Beräknad)
Primärt slutförande
Avslutad studie (Beräknad)
Avslutad studie
Studieregistreringsdatum
Först inskickad
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Första postat
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste uppdatering publicerad
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Senast verifierad
Mer information
Termer relaterade till denna studie
Andra studie-ID-nummer
Andra studie-ID-nummer
- 27924
- J7H-MC-KAAB (Annan identifierare: Eli Lilly and Company)
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .